AllianceBernstein’s Tourmaline Bio TRML Stock Holding History

AllianceBernstein’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-539,961	Closed	-$25.8M	–	3303
2025 Q3	$25.8M	Buy	539,961 +514,071	+1,986%	+$14.3M	0.01%	831
2025 Q2	$414K	Buy	25,890 +12,940	+100%	+$210K	﹤0.01%	2750
2025 Q1	$197K	Hold	12,950	–	–	﹤0.01%	2925
2024 Q4	$263K	Buy	12,950 +3,680	+40%	+$92.7K	﹤0.01%	2941
2024 Q3	$238K	Buy	+9,270	New	+$155K	﹤0.01%	2990
2023 Q2	–	Sell	-1,360	Closed	-$25.6K	–	3245
2023 Q1	$25.6K	Hold	1,360	–	–	﹤0.01%	3126
2022 Q4	$13.9K	Buy	+1,360	New	+$21.9K	﹤0.01%	3219

AllianceBernstein's TRML Position: Q4 2025 in Review

AllianceBernstein sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 539,961 shares — an estimated $25.8M sold.

AllianceBernstein first reported a position in TRML in Q4 2022 and held it in 7 quarters. The position peaked at $25.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

AllianceBernstein reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
AllianceBernstein sold 539,961 Tourmaline Bio shares in Q4 2025, an estimated $25.8M.
AllianceBernstein first reported a position in Tourmaline Bio in Q4 2022 and held it in 7 quarters.
AllianceBernstein's Tourmaline Bio position peaked at $25.8M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on AllianceBernstein's 13F filing for Q4 2025, filed 17 Feb 2026.